
Bal Pharma Ltd. — Investor Relations & Filings
Bal Pharma Ltd. specializes in the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Formulations. The organization operates manufacturing facilities compliant with international quality standards, including WHO-GMP certifications. Its product portfolio encompasses a wide range of therapeutic segments, including diabetology, cardiology, gastroenterology, oncology, and pain management. Notable APIs in its catalog include Gliclazide, Ebastine, and Benzydamine. The company maintains an integrated business model, supporting operations from research and development to large-scale production. Bal Pharma serves a global clientele, exporting its products to numerous international markets across multiple continents, while focusing on the delivery of high-quality medicinal products and specialized formulations.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Resignation of Director/KMP/SMP | 2026-05-12 | English | |
| Intimation on resignation of Company Secretary & Compliance officer. | 2026-05-12 | English | |
| Disclosure under SEBI Takeover Regulations | 2026-04-17 | English | |
| Structural Digital Database | 2026-04-15 | English | |
| Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-06 | English | |
| Trading Window | 2026-03-23 | English |
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Enzymatica AB
Develops medical devices for infections based on a propriet…
|
ENZY | SE | Manufacturing |
|
Epitomee Medical Ltd.
Develops ingestible therapeutic devices for chronic disease…
|
EPIT | IL | Manufacturing |
|
EPSILON HEALTHCARE LIMITED
Integrated medicinal cannabis company providing manufacturi…
|
EPN | AU | Manufacturing |
|
EQL Pharma AB
Develops and sells niche generic and specialty medicines, p…
|
EQL | SE | Manufacturing |
|
Erasca, Inc.
A clinical-stage oncology company developing therapies for …
|
ERAS | US | Manufacturing |
|
Eris Lifesciences Limited
Develops and markets branded generic pharmaceuticals for ch…
|
ERIS | IN | Manufacturing |
|
Ernexa Therapeutics Inc.
Biopharmaceutical company developing cell therapies for can…
|
ERNA | US | Manufacturing |
|
ERYTECH Pharma S.A.
Develops red blood cell-based therapies for cancer and orph…
|
ERYP | FR | Manufacturing |
|
Esperion Therapeutics, Inc.
Develops and commercializes oral medicines to reduce cardio…
|
ESPR | US | Manufacturing |
|
ESSA Pharma Inc.
Develops drugs targeting the androgen receptor's N-terminal…
|
EPIX | US | Manufacturing |
Bal Pharma Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/59392/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=59392 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=59392 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=59392 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 59392}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Bal Pharma Ltd. (id: 59392)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.